FR2946884B1 - NACRE COMPOSITION FOR USE IN THE TREATMENT OF NERVOUS LESIONS, NEUROGEN SUBSTRATE COMPRISING SAID COMPOSITION AND PROCESS FOR PREPARING THE SAME - Google Patents

NACRE COMPOSITION FOR USE IN THE TREATMENT OF NERVOUS LESIONS, NEUROGEN SUBSTRATE COMPRISING SAID COMPOSITION AND PROCESS FOR PREPARING THE SAME

Info

Publication number
FR2946884B1
FR2946884B1 FR0954084A FR0954084A FR2946884B1 FR 2946884 B1 FR2946884 B1 FR 2946884B1 FR 0954084 A FR0954084 A FR 0954084A FR 0954084 A FR0954084 A FR 0954084A FR 2946884 B1 FR2946884 B1 FR 2946884B1
Authority
FR
France
Prior art keywords
composition
neurogen
preparing
substrate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0954084A
Other languages
French (fr)
Other versions
FR2946884A1 (en
Inventor
Joel Drai
Serge Camprasse
Georges Camprasse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEGA BIO PHARMA, FR
Original Assignee
MEGA BIO PHARMA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEGA BIO PHARMA filed Critical MEGA BIO PHARMA
Priority to FR0954084A priority Critical patent/FR2946884B1/en
Priority to PCT/FR2010/051202 priority patent/WO2010146309A1/en
Publication of FR2946884A1 publication Critical patent/FR2946884A1/en
Application granted granted Critical
Publication of FR2946884B1 publication Critical patent/FR2946884B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0954084A 2009-06-17 2009-06-17 NACRE COMPOSITION FOR USE IN THE TREATMENT OF NERVOUS LESIONS, NEUROGEN SUBSTRATE COMPRISING SAID COMPOSITION AND PROCESS FOR PREPARING THE SAME Active FR2946884B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0954084A FR2946884B1 (en) 2009-06-17 2009-06-17 NACRE COMPOSITION FOR USE IN THE TREATMENT OF NERVOUS LESIONS, NEUROGEN SUBSTRATE COMPRISING SAID COMPOSITION AND PROCESS FOR PREPARING THE SAME
PCT/FR2010/051202 WO2010146309A1 (en) 2009-06-17 2010-06-16 Mother-of-pearl composition for using in the treatment of lesions in the nervous system, neurogenic substrate comprising said composition, and method for the production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0954084A FR2946884B1 (en) 2009-06-17 2009-06-17 NACRE COMPOSITION FOR USE IN THE TREATMENT OF NERVOUS LESIONS, NEUROGEN SUBSTRATE COMPRISING SAID COMPOSITION AND PROCESS FOR PREPARING THE SAME

Publications (2)

Publication Number Publication Date
FR2946884A1 FR2946884A1 (en) 2010-12-24
FR2946884B1 true FR2946884B1 (en) 2013-01-18

Family

ID=41360307

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0954084A Active FR2946884B1 (en) 2009-06-17 2009-06-17 NACRE COMPOSITION FOR USE IN THE TREATMENT OF NERVOUS LESIONS, NEUROGEN SUBSTRATE COMPRISING SAID COMPOSITION AND PROCESS FOR PREPARING THE SAME

Country Status (2)

Country Link
FR (1) FR2946884B1 (en)
WO (1) WO2010146309A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR954066A (en) 1947-09-26 1949-12-19 Improvements to machines for manufacturing twisted-core tracks
FR2719478B1 (en) * 1994-05-09 1996-07-26 Serge Camprasse Skin regeneration and healing product. Its manufacturing process its applications.
FR2777190B1 (en) 1998-04-14 2001-07-27 Georges Camprasse EXTRACTION PROCESS, IDENTIFICATION OF THE ACTIVE INGREDIENTS CONTAINED IN THE INTERNAL AND EXTERNAL SHELL OF SEA MOLLUSCS, THEIR USE IN PEOPLE-BASED THERA, DIAGNOSIS AND COSMETIC PREPARATIONS
FR2827478B1 (en) * 2001-07-18 2003-10-24 Jean Louis Montero PROCESS FOR THE PREPARATION OF A NACRE-BASED POWDER, ISOLATED PROTEIN FROM SAID POWDER AND THEIR USES IN BONE SURGERY AND IN VARIOUS OSTEOARTICULAR PATHOLOGIES

Also Published As

Publication number Publication date
WO2010146309A1 (en) 2010-12-23
FR2946884A1 (en) 2010-12-24

Similar Documents

Publication Publication Date Title
FR2942963B1 (en) COSMETIC COMPOSITION COMPRISING COLORING MATTER, COLORING MATERIAL, AND COSMETIC TREATMENT PROCESS
FR2932478B1 (en) COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS.
PL1975226T3 (en) Liquid treatment composition
CL2011000838A1 (en) Heterocyclic compounds derived from ortho-condensed tetracycles with a pyrimidine 2,4,6-trione spirocondensate group, bacterial DNA gyrase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a bacterial infection.
HK1148284A1 (en) Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions hif
ZA200907215B (en) Uses of oligomers of lactic acid in the treatment of gynaecological disorders
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
FR2934129B1 (en) COSMETIC TREATMENT PROCESS.
IL195152A (en) Compounds for use in the treatment of cell proliferative disorders
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
CL2013001591A1 (en) Compounds derived from triazolopyridine; pde10a inhibitors; obtaining process; pharmaceutical composition; and use in the treatment or prophylaxis of psychotic disorders, schizophrenia, anxiety, among other diseases.
CL2008000875A1 (en) COMPOUNDS DERIVED FROM IMIDAZOLIDIN-2-ONA; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PROFILAXIS OF DISEASES SUCH AS DYSLIPIDEMIA, DIABETES, INFLAMMATORY DISEASES, AMONG OTHERS.
CL2013002424A1 (en) Compounds derived from (pyridin-4-yl) -benzylamides as allosteric modulators of nachr alfa-7; pharmaceutical composition; process to prepare the pharmaceutical composition; and use in the treatment of diseases such as Alzheimer's, anxiety, schizophrenia, parkinson's, among others.
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
FR2933609B1 (en) USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE TREATMENT OF PARKINSON'S DISEASE.
CL2014001323A1 (en) Compounds derived from 3-phenyl-isoquinolin-1 (2h) -one, parp-1 inhibitors; preparation procedure; pharmaceutical composition; and use in the treatment of cancer.
DE602006018505D1 (en) PHOTOSTABILE PHARMACEUTICAL COMPOSITION WITH BRIVUDIN FOR THE TREATMENT OF HERPETIC KERATITIS
FR2957225B1 (en) PROCESS FOR THE ELEVATION OF SHELLAGES, IN PARTICULAR OYSTERS
FR2983733B1 (en) PHYTOECDYSONES FOR THEIR USE IN IMPROVING THE MUSCLE QUALITY OF OBESE AND / OR SARCOPENIC MAMMALS
FR2946884B1 (en) NACRE COMPOSITION FOR USE IN THE TREATMENT OF NERVOUS LESIONS, NEUROGEN SUBSTRATE COMPRISING SAID COMPOSITION AND PROCESS FOR PREPARING THE SAME
ZA201103134B (en) (pyrrolidin-2 yl) phenyl derivatives for use in the treatment of pain
FR2973376B1 (en) DERIVATIVES USEFUL IN THE TREATMENT OR PREVENTION OF BONE TUMORS
FR2950058B1 (en) USE OF BENZOIC INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE TREATMENT OF PARKINSON'S DISEASE
FR2930727B1 (en) COMPOSITION FOR THE TREATMENT OF SEBORRHEIC STATES.
FR2954141B1 (en) PROCESS FOR CAPTURING ACTIVE INGREDIENTS IN THE SKIN

Legal Events

Date Code Title Description
TP Transmission of property
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

TP Transmission of property

Owner name: MEGA BIO PHARMA, FR

Effective date: 20170227

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16